-
January 11, 2013
Johnson & Johnson is celebrating after advisors to the US Food and Drug Administration recommended approval for the diabetes treatment canagliflozin, despite safety concerns
Full story
-
November 09, 2012
Shares in Novo Nordisk have soared this morning after an FDA panel recommended approval of Tresiba and Ryzodeq, despite expressing concerns over possible cardiovascular risk of the ultra long-acting insulins
Full story
-
October 17, 2012
Advisors to the US Food and Drug Administration have given their backing to NPS Pharmaceuticals' Gattex for the treatment of short bowel syndrome
Full story
-
August 29, 2012
Abbott Laboratories looks likely to get another green light for Humira after advisors to the US Food and Drug Administration backed the blockbuster as a treatment for ulcerative colitis
Full story
-
July 30, 2012
Shares in ThromboGenics have soared after regulators in the USA recommended approval for the Belgian firm's eye drug ocriplasmin
Full story
-
May 11, 2012
The likelihood of a new obesity drug getting on the market in the USA soon has risen after advisors to the US Food and Drug Administration backed Arena Pharmaceuticals and Eisai's Lorqess
Full story
-
May 10, 2012
Pfizer is celebrating the news that advisors to the US Food and Drug Administration have recommended approval of tofacitinib, its oral Janus kinase (JAK) inhibitor for rheumatoid arthritis
Full story
-
February 24, 2012
Advisors to the US Food and Drug Administration have recommended approval for Forest Laboratories and Almirall’s chronic obstructive pulmonary disease drug aclidinium bromide
Full story
-
February 23, 2012
AstraZeneca's bid to push up market share of its new antiplatelet drug Brilinta has been helped by a recommendation from the influential American College of Chest Physicians
Full story
-
February 23, 2012
It looks as though Vivus' Qnexa is set to be the first prescription diet drug to reach the US market since 1999 after advisors to the FDA overwhelmingly recommended the pill for approval
Full story